C12N 15/1137
Against enzymes
Official title: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
C12N15/1137 (Against enzymes) appears on 2,851 US grants and 5,336 published applications in this corpus.
Search patents in C12N- Granted patents
- 2,851
- Published applications
- 5,336
- Assignees
- 1,586
- Inventors
- 8,318
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 7 | 0 |
| 1994 | 7 | 0 |
| 1995 | 9 | 0 |
| 1996 | 21 | 0 |
| 1997 | 39 | 0 |
| 1998 | 45 | 0 |
| 1999 | 72 | 0 |
| 2000 | 69 | 0 |
| 2001 | 69 | 12 |
| 2002 | 66 | 40 |
| 2003 | 46 | 169 |
| 2004 | 38 | 167 |
| 2005 | 16 | 153 |
| 2006 | 30 | 80 |
| 2007 | 26 | 119 |
| 2008 | 32 | 115 |
| 2009 | 58 | 200 |
| 2010 | 69 | 183 |
| 2011 | 71 | 181 |
| 2012 | 113 | 165 |
| 2013 | 96 | 214 |
| 2014 | 131 | 226 |
| 2015 | 144 | 282 |
| 2016 | 147 | 267 |
| 2017 | 167 | 249 |
| 2018 | 170 | 223 |
| 2019 | 159 | 244 |
| 2020 | 157 | 242 |
| 2021 | 147 | 272 |
| 2022 | 127 | 281 |
| 2023 | 129 | 338 |
| 2024 | 108 | 346 |
| 2025 | 144 | 327 |
| 2026 | 119 | 241 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Inhibiting the RNA methyltransferase METTL3 or its interaction with EIF3H to suppress oncogene translation and tumorigenesis22 Sep 2026US 12,742,021 B2Children's Medical Center Corporation
- Methods and compositions for inactivating interleukin-2-inducible t-cell kinase (ITK)8 Sep 2026US 12,729,381 B2The Research Foundation for The State University of New York
- Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression1 Sep 2026US 12,723,247 B2Alnylam Pharmaceuticals, Inc.
- Pharmaceutical composition containing HERES expression inhibitor for preventing or treating squamous cell carcinoma25 Aug 2026US 12,716,066 B2Industry-Academic Cooperation Foundation, Yonsei University
- Modulation of GYS1 expression25 Aug 2026US 12,716,067 B2Ionis Pharmaceuticals, Inc.
- Modified adeno-associated virus vector and use thereof in treating neurological diseases8 Oct 2026US 2026/0306673 A1Genecombio Ltd.
- Precision immunosuppression as prevention and therapy for graft-versus-host disease8 Oct 2026US 2026/0308592 A1
- Treatment of gpam related diseases and disorders8 Oct 2026US 2026/0308594 A1Empirico Inc.
- Sirt1 inhibitor or antagonist for use in preventing and/or treating an hpv induced tumour1 Oct 2026US 2026/0294868 A1Universita Degli Studi Del Piemonte Orientale “A. Avogadro”
- Universal treatment of down syndrome1 Oct 2026US 2026/0294978 A1DEI Biopharma
Most cited
By later US patents
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997
- Oligonucleotides having phosphorothioate linkages of high chiral purity626US 5,587,361 AIsis Pharmaceuticals, Inc. · 1996
- Oligonucleotides containing N-2 substituted purines621US 5,587,469 AIsis Pharmaceuticals, Inc. · 1996
- Substituted purines and oligonucleotide cross-linking603US 5,681,941 AIsis Pharmaceuticals, Inc. · 1997